Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Returning to Baseline in 2 Years: Individuals Regain Weight More Quickly After Halting Obesity Medications Than Following a Diet - Featured image
Health

Returning to Baseline in 2 Years: Individuals Regain Weight More Quickly After Halting Obesity Medications Than Following a Diet

A University of Oxford study indicates that weight loss from medications like GLP-1 drugs often rebounds quickly upon cessation, faster than after dieting and exercise. Behavioral programs lead to slower regain, emphasizing sustainable lifestyle changes. Obesity impacts billions globally, raising risks for heart disease and diabetes.

Shotlee·January 8, 2026·Updated Jan 27, 2026·2 min read
Share:

The results hold importance since roughly half of individuals with obesity discontinue the use of GLP-1 medications, which function by imitating a natural gut hormone to curb hunger, within 12 months. This suggests that "medications by themselves might not suffice for prolonged weight management," as stated by experts from the University of Oxford.

The investigation contrasted various types of weight-reduction treatments—including earlier GLP-1 options and advanced versions such as semaglutide or tirzepatide featured in Novo Nordisk A/S's Ozempic and Eli Lilly & Co.'s Mounjaro—with data from a prior analysis of behavioral weight-control initiatives that encompassed dieting and physical activity.

Researchers examined 37 studies released by February 2025, which included 9,341 volunteers.

For those who utilized semaglutide or tirzepatide, the projected pace of weight recovery was anticipated to exceed the norm, potentially reaching the initial weight within roughly 18 months, based on the findings.

In addition to weight recovery, the research demonstrated that discontinuing medications results in the loss of other advantages, including enhancements in cardiovascular and metabolic indicators such as decreased cholesterol and lower blood pressure.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Conversely, behavioral weight-management approaches that emphasize enduring modifications like decreased calorie consumption and heightened exercise correlated with a more gradual return of weight.

Obesity impacts almost two billion grown-ups across the globe, per the BMJ, and markedly elevates the likelihood of cardiovascular issues, diabetes, and early mortality.

Certain experts remarked that the findings should not be unexpected.

"We do not anticipate treatments for chronic conditions to persist after cessation, and there's no rationale to believe obesity would differ," commented John Wilding, a professor of medicine at the University of Liverpool and contributor to one of the examined trials.

Health tracking applications such as Shotlee can assist in overseeing progress during weight management journeys.

Original source: ThePrint

View original article →
#obesity#weight loss drugs#GLP-1 medications#behavioral weight management#weight regain#semaglutide#tirzepatide#diet and exercise
  1. Home
  2. Blog
  3. Returning to Baseline in 2 Years: Individuals Regain Weight More Quickly After Halting Obesity Medications Than Following a Diet

Related Articles

Tirzepatide Adverse Events: Subgroup Differences Explored
GLP-1 Medications

Tirzepatide Adverse Events: Subgroup Differences Explored

A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.

Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
GLP-1 Medications

Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry

Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.

NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions
GLP-1 Medications

NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions

The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community